Rigel’s stock rocked as all-in drug disappoints in late-stage trial
October 20, 2016 at 14:24 PM EDT
Rigel Pharmaceuticals’ stock plunges after its ITP treatment, which it cut nearly half its workforce to focus on, missed the primary goal in a phase 3 trial.
